


# Fuchs Endothelial Corneal Dystrophy Market and Epidemiology 2032: Treatment Market, Therapies, Companies | DelveInsight

*DelveInsight's Fuchs Endothelial Corneal Dystrophy Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.*

NEVADA, LAS VEGAS, UNITED STATES, March 26, 2024 /EINPresswire.com/ -- DelveInsight's "[Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2032](#)" report offers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the Fuchs Endothelial Corneal Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.



To Know in detail about the Fuchs Endothelial Corneal Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Fuchs Endothelial Corneal Dystrophy Market Forecast](#)

Some of the key facts of the Fuchs Endothelial Corneal Dystrophy Market Report:

The Fuchs Endothelial Corneal Dystrophy market size was valued approximately USD 846 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032). The total prevalent Fuchs Endothelial Corneal Dystrophy cases in the 7MM were estimated to be approximately 17,499,877 cases in the year 2021 which are expected to increase by 2032. In 2021, among the 7MM, the US had the highest total prevalent cases of Fuchs Endothelial Corneal Dystrophy with about 6,450,491 cases while Spain had the lowest with 1,271,604 cases in 2021.

Among the EU-5 countries, Germany had the highest prevalent cases of FECD with 2,132,532 cases in 2021 followed by Italy and France.

Key Fuchs Endothelial Corneal Dystrophy Companies: Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Novartis AG, Kowa Company, Ltd., Trefoil Therapeutics, AERIE PHARMACEUTICALS, INC., Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc.,

GlaxoSmithKline plc, Bausch Health Companies Inc., and others

Key Fuchs Endothelial Corneal Dystrophy Therapies: Ripasudil(K-321), TTHX1114, STN1010904/AE-001, EO2002, K-321 Solution, Elamipretide, and others

The Fuchs Endothelial Corneal Dystrophy epidemiology based on gender analyzed that Fuchs Endothelial Corneal Dystrophy is more prominent in females in comparison to males

The Fuchs Endothelial Corneal Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fuchs Endothelial Corneal Dystrophy pipeline products will significantly revolutionize the Fuchs Endothelial Corneal Dystrophy market dynamics.

### Fuchs Endothelial Corneal Dystrophy Overview

Fuchs Endothelial Corneal Dystrophy (FECD) is a genetic eye disorder that affects the cornea, which is the clear, dome-shaped surface that covers the front of the eye. In FECD, there is a gradual deterioration of the endothelial cells, which are responsible for maintaining the proper balance of fluid within the cornea.

Get a Free sample for the Fuchs Endothelial Corneal Dystrophy Market Report:

[https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=gpr](https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr)

### Fuchs Endothelial Corneal Dystrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

### Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation:

The Fuchs Endothelial Corneal Dystrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Fuchs Endothelial Corneal Dystrophy

Prevalent Cases of Fuchs Endothelial Corneal Dystrophy by severity

Gender-specific Prevalence of Fuchs Endothelial Corneal Dystrophy

Diagnosed Cases of Episodic and Chronic Fuchs Endothelial Corneal Dystrophy

Download the report to understand which factors are driving Fuchs Endothelial Corneal Dystrophy epidemiology trends @ [Fuchs Endothelial Corneal Dystrophy Epidemiology Forecast](#)

### Fuchs Endothelial Corneal Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fuchs Endothelial Corneal Dystrophy market or expected to get launched during the study period. The analysis covers Fuchs Endothelial Corneal Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fuchs Endothelial Corneal Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

#### Fuchs Endothelial Corneal Dystrophy Therapies and Key Companies

Ripasudil(K-321): Kowa Pharmaceuticals

TTHX1114: Trefoil Therapeutics

STN1010904/AE-001: Santen Pharmaceutical/ ActualEyes Inc

EO2002: Emmecel

K-321 Solution: Kowa Research Institute, Inc.

#### Fuchs Endothelial Corneal Dystrophy Market Drivers

Development of novel pharmacological adjuncts

Cultured human Corneal endothelial cells: The next revolution in corneal endothelial dysfunction

Development of gene therapies

Progressive use of less invasive therapy: DSOv Improved diagnostics

#### Fuchs Endothelial Corneal Dystrophy Market Barriers

Significant shortage of cornea donors

Lack of genetic classification of Fuchs Endothelial Corneal Dystrophy

Challenges in clinical trials: Dispersed patient population

High investment risk: Limited R&D

#### Scope of the Fuchs Endothelial Corneal Dystrophy Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Fuchs Endothelial Corneal Dystrophy Companies: Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Novartis AG, Kowa Company, Ltd., Trefoil Therapeutics, AERIE PHARMACEUTICALS, INC., Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc., GlaxoSmithKline plc, Bausch Health Companies Inc., and others

Key Fuchs Endothelial Corneal Dystrophy Therapies: Ripasudil(K-321), TTHX1114, STN1010904/AE-001, EO2002, K-321 Solution, Elamipretide, and others

Fuchs Endothelial Corneal Dystrophy Therapeutic Assessment: Fuchs Endothelial Corneal Dystrophy current marketed and Fuchs Endothelial Corneal Dystrophy emerging therapies

Fuchs Endothelial Corneal Dystrophy Market Dynamics: Fuchs Endothelial Corneal Dystrophy market drivers and Fuchs Endothelial Corneal Dystrophy market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Fuchs Endothelial Corneal Dystrophy Unmet Needs, KOL's views, Analyst's views, Fuchs Endothelial Corneal Dystrophy Market Access and Reimbursement

To know more about Fuchs Endothelial Corneal Dystrophy companies working in the treatment market, visit @ [Fuchs Endothelial Corneal Dystrophy Treatment Market](#)

## Table of Contents

1. Fuchs Endothelial Corneal Dystrophy Market Report Introduction
2. Executive Summary for Fuchs Endothelial Corneal Dystrophy
3. SWOT analysis of Fuchs Endothelial Corneal Dystrophy
4. Fuchs Endothelial Corneal Dystrophy Patient Share (%) Overview at a Glance
5. Fuchs Endothelial Corneal Dystrophy Market Overview at a Glance
6. Fuchs Endothelial Corneal Dystrophy Disease Background and Overview
7. Fuchs Endothelial Corneal Dystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Fuchs Endothelial Corneal Dystrophy
9. Fuchs Endothelial Corneal Dystrophy Current Treatment and Medical Practices
10. Fuchs Endothelial Corneal Dystrophy Unmet Needs
11. Fuchs Endothelial Corneal Dystrophy Emerging Therapies
12. Fuchs Endothelial Corneal Dystrophy Market Outlook
13. Country-Wise Fuchs Endothelial Corneal Dystrophy Market Analysis (2019–2032)
14. Fuchs Endothelial Corneal Dystrophy Market Access and Reimbursement of Therapies
15. Fuchs Endothelial Corneal Dystrophy Market Drivers
16. Fuchs Endothelial Corneal Dystrophy Market Barriers
17. Fuchs Endothelial Corneal Dystrophy Appendix
18. Fuchs Endothelial Corneal Dystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

## About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/698907748>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.